Cleo Diagnostics Ltd (COV.AX)
- Previous Close
0.1950 - Open
0.1850 - Bid 0.1800 x --
- Ask 0.1850 x --
- Day's Range
0.1850 - 0.1850 - 52 Week Range
0.1400 - 0.2300 - Volume
15,001 - Avg. Volume
53,330 - Market Cap (intraday)
23.773M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development of non-invasive blood based IVD tests to detect the presence and recurrence of ovarian cancer in Australia. It focuses on the development of triage, recurrence, and screening tests for ovarian cancer detection. The company was incorporated in 2021 and is based in Melbourne, Australia.
www.cleodx.comRelated News
Performance Overview: COV.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: COV.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: COV.AX
Valuation Measures
Market Cap
23.77M
Enterprise Value
25.13M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.26
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-6.74
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
--
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--
Company Insights: COV.AX
COV.AX does not have Company Insights